Top

Published in:

01-10-2011 | Original Article

Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer?

Authors: Takayoshi Uematsu, Masako Kasami, Junichiro Watanabe, Kaoru Takahashi, Seiji Yamasaki, Kumiko Tanaka, Yukiko Tadokoro, Akiko Ogiya

Published in: Breast Cancer | Issue 4/2011

Abstract

Background

Patients who achieve pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) have favorable disease-free survival rates. A few studies have suggested that lymphovascular invasion degree may play an important role in predicting pCR. This study aims to confirm the role of lymphatic invasion degree in predicting pCR in breast cancer patients after NAC.

Methods

We retrospectively analyzed 120 patients treated with NAC and surgery. The following pathological features were evaluated on surgical specimens after NAC: histological grade, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), lymphovascular invasion degree, intratumoral necrosis positivity, and axillary lymph node positivity.

Results

pCR and marked response were achieved in 12% (14/120) and 35% (42/120), respectively, of 120 breast cancers in 120 women. Breast cancers with pCR or marked response were classified as chemosensitive. The remaining 64 breast cancers (53%) were classified as chemoresistant. Severe lymphovascular invasion (P = .003), large tumor size (P = .029), ER positivity (P = .001), and PR positivity (P = .006) were significantly associated with chemoresistant breast cancer. Invasive ductal carcinoma (P = .028) and HER-2 positivity (P < .0001) were significantly associated with chemosensitive breast cancer. On multivariate analysis, HER-2 positivity (P < .0001), invasive ductal carcinoma (P = .047), and marked/moderate lymphovascular invasion (P = .023) were the three factors that remained statistically significant in the model to predict histological therapeutic effect.

Conclusion

Lymphovascular invasion degree is one of the important factors to predict NAC efficacy for breast cancer.

Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 2008;26:778–85.PubMedCrossRef

Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operative disease. J Clin Oncol. 2008;26:814–9.PubMedCrossRef

Tamura N, Hasebe T, Okada N, Houjoh T, Akashi-Tanaka S, Shimizu C, et al. Tumor histology in lymph vessels and lymph nodes for the accurate prediction of outcome among breast cancer patients treated with neoadjuvant chemotherapy. Cancer Sci. 2009;100:1823–33.PubMedCrossRef

Sullivan PS, Apple SK. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma? Breast J. 2009;15:146–54.PubMedCrossRef

Lauria R, Perrone F, Carlomagno C, De Laurentiis M, Morabito A, Gallo C, et al. The prognostic value of lymphatic and blood vessel invasion in operative breast cancer. Cancer. 1995;76:1772–8.PubMedCrossRef

Hasebe T, Sasaki S, Imoto S, Ochiai A. Characteristics of tumors in lymph vessels play an important role in the tumor progression of invasive ductal carcinoma of the breast: a prospective study. Mod Pathol. 2001;15:904–13.CrossRef

Hasebe T, Okada N, Iwasaki M, Akashi-Tanaka S, Hojo T, Shibata T, et al. Grading system for lymph vessel tumor emboli: significant outcome predictor for invasive ductal carcinoma of the breast. Mod Pathol. 2010. doi:10.1016/j.humpath.2009.10.015.

Egan RL. Multicentric breast carcinomas: clinical-radiographic–pathologic whole organ studies and 10-year survival. Cancer. 1982;49:1123–30.PubMedCrossRef

Kurosumi M, Akashi-Tanaka S, Akiyama F, Komoike Y, Mukai H, et al. Histopathological criteria for assessment of therapeutic response in breast cancer (2007 version). Breast Cancer. 2008;15:5–7.PubMedCrossRef

10.

Fisher ER, Anderson S, Redmond C, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project B-06. 10-year pathologic and clinical prognostic discriminants. Cancer. 1993;71:2507–14.PubMedCrossRef

11.

Jimenez RE, Wallis T, Visscher DW. Centrally necrotizing carcinoma of the breast: a distinct histologic subtype with aggressive clinical behavior. Am J Surg Pathol. 2001;25:331–7.PubMedCrossRef

12.

Leek RD, Landers RJ, Harris AL, Lewis CE. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer. 1999;79:991–5.PubMedCrossRef

13.

Tubiana-Hulin M, Stevens D, Lasry S, Guinebretière JM, Bouita L, Cohen-Solal C, et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol. 2006;17:1228–33.PubMedCrossRef

14.

Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol. 2005;23:41–8.PubMedCrossRef

15.

Komenaka IK, El-Tamer MB, Troxel A, et al. Pure mucinous carcinoma of the breast. Am J Surg. 2004;187:528–32.PubMedCrossRef

16.

Yamaguchi J, Akashi-Tanaka S, Fukutomi T, Kinosita T, Iwamoto E, Takasugi M. A case of mucinous carcinoma of the breast that demonstrated a good pathological response to neoadjuvant chemotherapy despite a poor clinical response. Breast Cancer. 2006;13:100–3.PubMedCrossRef

17.

Chen JH, Feig B, Agrawal G, Yu H, Carpenter PM, Mehta RS, et al. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer. 2008;112:17–26.PubMedCrossRef

Title: Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer?
Authors: Takayoshi Uematsu
Masako Kasami
Junichiro Watanabe
Kaoru Takahashi
Seiji Yamasaki
Kumiko Tanaka
Yukiko Tadokoro
Akiko Ogiya
Publication date: 01-10-2011
Publisher: Springer Japan
Published in: Breast Cancer / Issue 4/2011
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-010-0211-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2011

Strategy of radiation therapy for bone metastases and MSCC in breast cancer patients

The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer

A case of a fibroadenoma coexisting with an invasive lobular carcinoma in the breast

Association between the −402GA, −401GT, and −323ins10-bp polymorphisms of factor VII gene and breast cancer

Oncoplastic surgery for Japanese patients with ptotic breasts

Synchronous benign-appearing calcifications in patients with ductal carcinoma in situ may not be benign

Keynote webinar | Spotlight on antibody–drug conjugates in cancer